Metastatic prostate cancer remains a life-limiting disease; while we have seen significant advances in systemic approaches which form the backbone of management, no curative paradigm yet exists. Metastasis-directed therapy (MDT) with stereotactic ablative radiotherapy (SABR) has emerged as a promising complementary technique for the management of low-volume metastatic prostate cancer. Herein we will review the rationale, potential benefits, and practical considerations associated with this approach.
|Original language||English (US)|
|Number of pages||6|
|Journal||ONCOLOGY (United States)|
|State||Published - 2019|
ASJC Scopus subject areas
- Cancer Research